Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

Clinical trial NCT05987956 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05987956
Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Start date: 2026-03-18
Primary completion: 2026-11-18
Enrollment: 600

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.